Parkinson’s disease now affects nearly 150,000 patients in France, most of them elderly people. The hope of fighting against this particularly debilitating disease is reborn with the discovery of rasagiline. According to researchers from Inserm (National Institute of Health and Medical Research), this drug not only fights the symptoms of the disease, it also slows its progression. Tests have in fact been carried out on 1,200 patients, some treated for 18 months and others for only 9 months. At the end of these studies, the researchers found that the group treated earlier had better results in terms of disease progression than those treated later. Rasagiline therefore has an effect on the progression of the disease and not only on the short-term symptoms.
